# Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support

> **NIH NIH R01** · VIRGINIA COMMONWEALTH UNIVERSITY · 2024 · $73,068

## Abstract

Project Abstract
This project is a training plan request for a Research Supplement to Promote Diversity in
Health-Related Research. This supplement is to the current award,1R01HL164508-01A1
“Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or
acute respiratory distress syndrome patients receiving different modes of ventilation support”. In
this supplement, the PI and Co-Is on the parent award will co-mentor a female, African
American, PhD student enrolled in the VCU Pharmaceutical Engineering Program. The team
has experience mentoring students from diverse backgrounds, and they have worked with the
student to develop a training plan within the scope of the parent award. The student’s research
training goals will be to investigate the role of nucleotide oligomerization domain-like receptor
family pyrin domain containing 3 (NLRP3) inflammasome in the lung injury and systemic
inflammation following ventilator induced lung injury (VILI) with and without treatment with our
novel therapeutic. In the first aim, she will Evaluate lung and systemic inflammation metrics and
histology for the spray-dried surfactant aerosol formulations in rat VILI model. In the second
aim, she will test a dual therapeutic with the leading aerosolized surfactant formulation
combined with an NLRP3 inflammasome small molecule inhibitor in reducing inflammation in
the rat VILI model. Through these research goals and related training and mentoring, the
student will achieve a skillset that will prepare her for a research career in the pharmaceutical
industry.

## Key facts

- **NIH application ID:** 11020319
- **Project number:** 3R01HL164508-02S1
- **Recipient organization:** VIRGINIA COMMONWEALTH UNIVERSITY
- **Principal Investigator:** P. Worth Longest
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $73,068
- **Award type:** 3
- **Project period:** 2023-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11020319

## Citation

> US National Institutes of Health, RePORTER application 11020319, Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support (3R01HL164508-02S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11020319. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*